Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

AAALAC International Standards and Accreditation Process.

Gettayacamin M, Retnam L.

Toxicol Res. 2017 Jul;33(3):183-189. doi: 10.5487/TR.2017.33.3.183. Epub 2017 Jul 15. Review.

2.

Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model.

Teja-Isavadharm P, Siriyanonda D, Rasameesoraj M, Limsalakpeth A, Chanarat N, Komcharoen N, Weina PJ, Saunders DL, Gettayacamin M, Scott Miller R.

Malar J. 2016 Sep 6;15:453. doi: 10.1186/s12936-016-1456-6.

3.

Challenges and Opportunities in Implementation: The AAALAC International Perspective.

Guillén J, Gettayacamin M, Swearengen JR.

ILAR J. 2016 May 1;57(3):368-377. doi: 10.1093/ilar/ilw014.

PMID:
29117397
4.

A Review of Plasmodium coatneyi-Macaque Models of Severe Malaria.

Lombardini ED, Gettayacamin M, Turner GD, Brown AE.

Vet Pathol. 2015 Nov;52(6):998-1011. doi: 10.1177/0300985815583098. Epub 2015 Jun 15. Review.

PMID:
26077782
5.

Anti-relapse activity of mirincamycin in the Plasmodium cynomolgi sporozoite-infected Rhesus monkey model.

Fracisco S, Teja-isavadharm P, Gettayacamin M, Berman J, Li Q, Melendez V, Saunders D, Xie L, Ohrt C.

Malar J. 2014 Oct 17;13:409. doi: 10.1186/1475-2875-13-409.

6.

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, Chen Z, Francek C, Wu T, Nagle A, Barnes SW, Plouffe D, Lee MC, Fidock DA, Graumans W, van de Vegte-Bolmer M, van Gemert GJ, Wirjanata G, Sebayang B, Marfurt J, Russell B, Suwanarusk R, Price RN, Nosten F, Tungtaeng A, Gettayacamin M, Sattabongkot J, Taylor J, Walker JR, Tully D, Patra KP, Flannery EL, Vinetz JM, Renia L, Sauerwein RW, Winzeler EA, Glynne RJ, Diagana TT.

Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.

7.

Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.

Nanayakkara NP, Tekwani BL, Herath HM, Sahu R, Gettayacamin M, Tungtaeng A, van Gessel Y, Baresel P, Wickham KS, Bartlett MS, Fronczek FR, Melendez V, Ohrt C, Reichard GA, McChesney JD, Rochford R, Walker LA.

Antimicrob Agents Chemother. 2014 Aug;58(8):4737-44. doi: 10.1128/AAC.02674-13. Epub 2014 Jun 9.

8.

Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.

DiTusa C, Kozar MP, Pybus B, Sousa J, Berman J, Gettayacamin M, Im-erbsin R, Tungtaeng A, Ohrt C.

J Parasitol. 2014 Oct;100(5):671-3. doi: 10.1645/13-480.1. Epub 2014 Apr 29.

PMID:
24780070
9.

Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the pre-clinical assessment of Shigella vaccine formulations.

Islam D, Ruamsap N, Khantapura P, Aksomboon A, Srijan A, Wongstitwilairoong B, Bodhidatta L, Gettayacamin M, Venkatesan MM, Mason CJ.

APMIS. 2014 Jun;122(6):463-75. doi: 10.1111/apm.12168. Epub 2013 Sep 13.

10.

Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.

Deye GA, Gettayacamin M, Hansukjariya P, Im-erbsin R, Sattabongkot J, Rothstein Y, Macareo L, Fracisco S, Bennett K, Magill AJ, Ohrt C.

Am J Trop Med Hyg. 2012 Jun;86(6):931-5. doi: 10.4269/ajtmh.2012.11-0552.

11.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

12.

Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.

Milner E, Gardner S, Moon J, Grauer K, Auschwitz J, Bathurst I, Caridha D, Gerena L, Gettayacamin M, Johnson J, Kozar M, Lee P, Leed S, Li Q, McCalmont W, Melendez V, Roncal N, Sciotti R, Smith B, Sousa J, Tungtaeng A, Wipf P, Dow G.

J Med Chem. 2011 Sep 22;54(18):6277-85. doi: 10.1021/jm200647u. Epub 2011 Aug 22.

PMID:
21854078
13.

Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).

Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C.

Malar J. 2011 Jul 29;10:212. doi: 10.1186/1475-2875-10-212.

14.

Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum.

Milner E, Sousa J, Pybus B, Melendez V, Gardner S, Grauer K, Moon J, Carroll D, Auschwitz J, Gettayacamin M, Lee P, Leed S, McCalmont W, Norval S, Tungtaeng A, Zeng Q, Kozar M, Read KD, Li Q, Dow G.

Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):151-8. doi: 10.1007/s13318-011-0047-8. Epub 2011 Jul 13.

PMID:
21751074
15.

Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.

Van Gessel Y, Klade CS, Putnak R, Formica A, Krasaesub S, Spruth M, Cena B, Tungtaeng A, Gettayacamin M, Dewasthaly S.

Vaccine. 2011 Aug 11;29(35):5925-31. doi: 10.1016/j.vaccine.2011.06.062. Epub 2011 Jun 30.

PMID:
21723353
16.

A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.

Opsenica I, Burnett JC, Gussio R, Opsenica D, Todorović N, Lanteri CA, Sciotti RJ, Gettayacamin M, Basilico N, Taramelli D, Nuss JE, Wanner L, Panchal RG, Solaja BA, Bavari S.

J Med Chem. 2011 Mar 10;54(5):1157-69. doi: 10.1021/jm100938u. Epub 2011 Jan 25.

17.

Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum.

Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1347-51. doi: 10.1016/j.bmcl.2010.01.001. Epub 2010 Jan 7.

PMID:
20097070
18.

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.

PMID:
19857448
19.

Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.

Dow GS, Chen Y, Andrews KT, Caridha D, Gerena L, Gettayacamin M, Johnson J, Li Q, Melendez V, Obaldia N 3rd, Tran TN, Kozikowski AP.

Antimicrob Agents Chemother. 2008 Oct;52(10):3467-77. doi: 10.1128/AAC.00439-08. Epub 2008 Jul 21.

20.

Malaria causal prophylactic activity of imidazolidinedione derivatives.

Guan J, Wang X, Smith K, Ager A, Gettayacamin M, Kyle DE, Milhous WK, Kozar MP, Magill AJ, Lin AJ.

J Med Chem. 2007 Nov 29;50(24):6226-31. Epub 2007 Oct 30.

PMID:
17967003
21.

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Pichyangkul S, Kum-Arb U, Yongvanitchit K, Limsalakpetch A, Gettayacamin M, Lanar DE, Ware LA, Stewart VA, Heppner DG, Mettens P, Cohen JD, Ballou WR, Fukuda MM.

Infect Immun. 2008 Jan;76(1):229-38. Epub 2007 Oct 22.

22.

Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.

Dow GS, Heady TN, Bhattacharjee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldia N 3rd, Roncal N, Shearer T, Smith PL, Tungtaeng A, Wolf L, Cabezas M, Yourick D, Smith KS.

Antimicrob Agents Chemother. 2006 Dec;50(12):4132-43. Epub 2006 Sep 11.

23.

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP.

J Infect Dis. 2006 Jun 15;193(12):1658-65. Epub 2006 May 9.

PMID:
16703509
24.

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

Walsh DS, Gettayacamin M, Leitner WW, Lyon JA, Stewart VA, Marit G, Pichyangkul S, Gosi P, Tongtawe P, Kester KE, Holland CA, Kolodny N, Cohen J, Voss G, Ballou WR, Heppner DG Jr.

Vaccine. 2006 May 8;24(19):4167-78. Epub 2006 Mar 6.

PMID:
16574282
25.

Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.

Ajariyakhajorn C, Mammen MP Jr, Endy TP, Gettayacamin M, Nisalak A, Nimmannitya S, Libraty DH.

Antimicrob Agents Chemother. 2005 Nov;49(11):4508-14.

26.

Establishment of a non-human primate Campylobacter disease model for the pre-clinical evaluation of Campylobacter vaccine formulations.

Islam D, Lewis MD, Srijan A, Bodhidatta L, Aksomboon A, Gettayacamin M, Baqar S, Scott D, Mason CJ.

Vaccine. 2006 May 1;24(18):3762-71. Epub 2005 Jul 25.

PMID:
16098634
27.

Antimalarial activities and therapeutic properties of febrifugine analogs.

Jiang S, Zeng Q, Gettayacamin M, Tungtaeng A, Wannaying S, Lim A, Hansukjariya P, Okunji CO, Zhu S, Fang D.

Antimicrob Agents Chemother. 2005 Mar;49(3):1169-76.

28.

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS.

Vaccine. 2004 Sep 28;22(29-30):3831-40.

PMID:
15364429
29.

Transmission of STLV in a closed colony of macaques.

Parrish SW, Brown AE, Chanbancherd P, Gettayacamin M, Parrish JH.

Am J Primatol. 2004 Jun;63(2):103-9.

PMID:
15195332
30.

Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.

Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, Kester KE, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG Jr.

Am J Trop Med Hyg. 2004 May;70(5):499-509.

PMID:
15155981
31.

Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents.

Li QG, Mog SR, Si YZ, Kyle DE, Gettayacamin M, Milhous WK.

Am J Trop Med Hyg. 2002 May;66(5):516-25.

PMID:
12201585
32.

Vaginal Cytology of the Lesser Bandicoot Rat (Bandicota savilei).

Gettayacamin M, Hansukjariya P, Corcoran KD, Young GD, Macmillan JG.

Contemp Top Lab Anim Sci. 1999 Jan;38(1):76-80.

PMID:
12086458
33.

Isolation and characterization of rhesus blood dendritic cells using flow cytometry.

Pichyangkul S, Saengkrai P, Yongvanitchit K, Limsomwong C, Gettayacamin M, Walsh DS, Stewart VA, Ballou WR, Heppner DG.

J Immunol Methods. 2001 Jun 1;252(1-2):15-23.

PMID:
11334961
34.

Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei.

Petras JM, Young GD, Bauman RA, Kyle DE, Gettayacamin M, Webster HK, Corcoran KD, Peggins JO, Vane MA, Brewer TG.

Anat Embryol (Berl). 2000 May;201(5):383-97.

PMID:
10839633
35.

Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys.

Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):343-9.

PMID:
10466959
36.

Production of lethal infection that resembles fatal human disease by intranasal inoculation of macaques with Japanese encephalitis virus.

Myint KS, Raengsakulrach B, Young GD, Gettayacamin M, Ferguson LM, Innis BL, Hoke CH Jr, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):338-42.

PMID:
10466958
37.

An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys.

Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW.

Am J Trop Med Hyg. 1999 Mar;60(3):329-37.

PMID:
10466957
38.

Arteether: risks of two-week administration in Macaca mulatta.

Petras JM, Kyle DE, Gettayacamin M, Young GD, Bauman RA, Webster HK, Corcoran KD, Peggins JO, Vane MA, Brewer TG.

Am J Trop Med Hyg. 1997 Apr;56(4):390-6.

PMID:
9158046

Supplemental Content

Loading ...
Support Center